Safety data sheet
Standardized safety protocols and material specifications for professional use.
Certificate of Analysis
Purity verified via High-Performance Liquid Chromatography (HPLC) for #myo-tirzepatide-15mg
Tirzepatide (15mg)
Ultra High >99.5% Purity
Authorized Resellers
Available through our trusted partners
123peptide.com
Netherlands · Europe
local_shipping2-3 Business Days
Depeptidenwinkel.com
Netherlands · Europe
local_shipping2-3 Business Days
Scientific Background
Looking for a mid-sized vial that offers flexibility for progressive dosing? This 15mg option provides a practical balance for those building up to higher levels while enjoying tirzepatide's powerful dual-receptor benefits.
This advanced peptide simultaneously activates GLP-1 and GIP receptors to replicate incretin hormone actions, resulting in better insulin response, decreased food consumption, and improved calorie utilization. Studies show it outperforms single-receptor agents in reducing glucose and weight.
Its approximately five-day half-life enables weekly dosing. Clinical data reveal dose-related weight decreases up to 20-22% over long terms, excelling in obesity treatment.
Intended Research Use
- Drives notable weight loss (20-22% in trials)
- Boosts glucose management and lowers HbA1c
- Decreases glucagon secretion
- Delays stomach emptying for improved satiety
- Suppresses appetite and increases fullness signals
menu_bookScientific Publications
N Engl J Med (2022)
Tirzepatide once weekly for the treatment of obesity
open_in_newhttps://pubmed.ncbi.nlm.nih.gov/35658024/
StatPearls (2024)
Tirzepatide
open_in_newhttps://www.ncbi.nlm.nih.gov/books/NBK585056/
Front Endocrinol (2022)
GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes and obesity
open_in_newhttps://pubmed.ncbi.nlm.nih.gov/36313743/
Lancet (2018)
Efficacy and safety of LY3298176 (tirzepatide) in patients with type 2 diabetes
open_in_newhttps://pubmed.ncbi.nlm.nih.gov/30291013/
Clinical Evidence: Tirzepatide's GLP-1/GIP dual mechanism yields stronger weight loss (20-22% at 72 weeks) and HbA1c drops (2-2.5%) than semaglutide's GLP-1-only (15-17% weight, 1.5-2% HbA1c). It may have comparable GI effects but superior efficacy.
FOR RESEARCH USE ONLY. This product is intended for laboratory research purposes only and is not for human consumption, medical, or diagnostic use.
Possible stacks with other peptides
Synergistic combinations for enhanced research outcomes
Clinical research suggests combining Tirzepatide with complementary peptides can enhance weight management and metabolic outcomes.
Cagrilintide (5mg vial)
arrow_forwardmyo-cagrilintide-5mg
For added amylin effects, boosting satiety and potentially amplifying weight loss.
Tesamorelin (10mg vial)
arrow_forwardmyo-tesamorelin-10mg
Adds GH stimulation, targeting visceral fat while tirzepatide handles overall mass.
MOTS-c (10mg vial)
arrow_forwardmyo-mots-c-10mg
For mitochondrial support, enhancing energy and metabolic efficiency during therapy.
BPC-157 (5mg vial)
arrow_forwardmyo-bpc-157-5mg
To aid gut health and recovery, offsetting any GI side effects.
Semaglutide 5mg (5mg vial)
arrow_forwardmyo-semaglutide-5mg
Comparable GLP-1 agonist for appetite suppression — studied alongside Tirzepatide for weight loss protocol comparison and sequential research designs.
Retatrutide 10mg (10mg vial)
arrow_forwardmyo-retatrutide-10mg
Triple GLP-1/GIP/glucagon agonist with reported fat reduction up to 24% — investigated as an advanced alternative to Tirzepatide's dual mechanism.
CagriSema (Semaglutide + Cagrilintide) (5mg + 5mg vial)
arrow_forwardmyo-semaglutide-plus-cagrilintide-5mg-5mg
GLP-1 plus amylin dual-action blend offering complementary satiety mechanisms alongside Tirzepatide's incretin pathway for enhanced weight management research.
Cycling Note: Once-weekly subcutaneous injection for 12-16+ weeks.
